Management of Cataplexy in Narcolepsy

First-Line Treatments

• The American Academy of Sleep Medicine recommends sodium oxybate as a first-line treatment for cataplexy in narcolepsy patients, which is FDA-approved for treating both cataplexy and excessive daytime sleepiness 1, 2
• Pitolisant, a histamine-3-receptor inverse agonist, is also effective for cataplexy management and is not a controlled substance 4, 1

Pathophysiological Insights

• The loss of hypothalamic neurons that produce orexin/hypocretin in type 1 narcolepsy (with cataplexy) suggests that adrenergic systems are downstream mediators of this pathology 6, 7

Clinical Monitoring

• Regular monitoring for cataplexy exacerbation is essential if any medication affecting adrenergic systems is initiated, as recommended by the American Geriatrics Society 5